For investors who do not know that QIDP is infectious disease version of the FDA's Orphan Drug Status....Fast Track and Priority Review includes "rolling submission" of PhaseIII data pre-NDA. For those interested in selling immediately after PhaseIII data release let me recommend not to. Once NDA is filed FDA decision will come within 3 months. Institutions will be buying the shares you sell post-PhaseIII data release.
Rico, Biotechs in general have been a little week except our favorite stock. There is a lot of naysayers claiming that the PhaseIII results are already factored into the share price. I disagree. A more efficacious, less toxic replacement for Linezolid is about to be fast-tracked to approval for a company with less than 50 million shares outstanding, an ex-US deal with Bayer, is a stock that has been overlooked and undervalued by wallStreet. Stay the course and this company gets bought out by multiple of today's share price.
Your absolutly right, TSRX becomes a RISK OFF stock based on P3 results and the street will be loading up for the longterm. I will be buying more shares if I can get them cheap enough on dips after positive P3 results.